Inovio Pharmaceuticals Targets Transformation of Monoclonal Antibody Therapies

In this study in mice, a prototype monoclonal antibody construct encoding for an established anti-HIV monoclonal antibody was created as a DNA plasmid using Inovio's patented DNA optimization technology, including codon/RNA optimization and leader sequence utilization, and delivered with its CELLECTRA adaptive electroporation device.

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Inovio-Pharmaceuticals-Targets-Transformation-of-M/ArticleNewsFeed/Article/detail/823767?ref=25